Equities Research Analysts’ updated eps estimates for Tuesday, November 12th:
Amgen (NASDAQ:AMGN) had its buy rating reaffirmed by analysts at Jefferies Financial Group Inc.. The firm currently has a $380.00 target price on the stock.
Apogee Therapeutics (NASDAQ:APGE) had its outperform rating reiterated by analysts at Wedbush. Wedbush currently has a $87.00 price target on the stock.
Cogent Biosciences (NASDAQ:COGT) had its neutral rating reaffirmed by analysts at Wedbush. They currently have a $11.00 price target on the stock.
Fate Therapeutics (NASDAQ:FATE) had its neutral rating reiterated by analysts at Wedbush. Wedbush currently has a $5.00 target price on the stock.
StockNews.com started coverage on shares of FuelCell Energy (NASDAQ:FCEL). They issued a sell rating on the stock.
Disc Medicine (NASDAQ:IRON) had its outperform rating reiterated by analysts at Wedbush. The firm currently has a $83.00 target price on the stock, up from their previous target price of $75.00.
iTeos Therapeutics (NASDAQ:ITOS) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $25.00 price target on the stock.
Nuvalent (NASDAQ:NUVL) had its outperform rating reiterated by analysts at Wedbush. Wedbush currently has a $115.00 price target on the stock.
ORIC Pharmaceuticals (NASDAQ:ORIC) had its outperform rating reissued by analysts at Wedbush. The firm currently has a $20.00 target price on the stock.
StockNews.com began coverage on shares of Power REIT (NYSE:PW). StockNews.com issued a sell rating on the stock.
Sunrun (NASDAQ:RUN) had its hold rating reiterated by analysts at Truist Financial Co.. They currently have a $12.00 price target on the stock, down from their previous price target of $18.00.
Smith Douglas Homes (NYSE:SDHC) had its neutral rating reaffirmed by analysts at Wedbush. They currently have a $20.00 target price on the stock.
Shopify (NYSE:SHOP) (TSE:SHOP) had its neutral rating reissued by analysts at Wedbush. They currently have a $115.00 price target on the stock, up from their previous price target of $72.00.
StockNews.com initiated coverage on shares of TransAct Technologies (NASDAQ:TACT). They issued a hold rating on the stock.
Zeta Global (NYSE:ZETA) had its buy rating reissued by analysts at Truist Financial Co.. They currently have a $42.00 price target on the stock, up from their previous price target of $35.00.
Receive News & Ratings for Amgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc and related companies with MarketBeat.com's FREE daily email newsletter.
